In addition, the BU researchers have developed a new computational strategy to analyze this data and specifically identify key biological pathways (molecular circuits) that are active in cancer and "dormant" in normal cells. The study which appears in the November 25th issue of PLoS ONE, will ultimately lead to the development of drugs specifically aimed to inhibit these proteins.
According to the BU researchers, there are many features that make cancer cells different from normal cells. They look different histologically, they proliferate and divide at different rates, they are immortal unlike normal cells, and are less communicative with their neighbor cells. They are also more "selfish" in refusing to commit suicide (programmed cell death) which normal cells do when their genomes become unstable.
Much of the cellular machinery involved with these biological processes is controlled by a command control and communication system called signal transduction. Signal transduction is in large part controlled by a process called phosphorylation. When a protein is phosphorylated it either becomes active or repressed depending on its special function. "Therefore, identifying the phosphorylation status of proteins in cancer cells versus normal cells provides us with a unique ability to understand and perhaps intervene with the command and control center of cancer cells," said co-senior author Simon Kasif, PhD, who is the co-director of the Center of Advanced Genomic Technology and a professor in the department of biomedical engineering at BU. "Drugs are most effective on cancers when they attack the proteins that are activated," he added.
While cancers are highly heterogeous in their make-up, the BU researchers believe that a drug that would target this collection of proteins would be effective treatment for most lung cancers.
"This is the first statistically validated phosphopeptide signature to diagnose any disease, much less cancer or lung cancer," explained senior co-author Martin Steffen, MD, PhD, an assistant professor of pathology and laboratory medicine at BUSM, and director, Proteomics Core Facility at BUSM.
This research was performed in collaboration with Cell Signaling Technology employing their Phosphoscan "test kit".
A follow-up study is currently underway at BU to identify which cancers respond or not respond to existing cancer drugs based on the results of this test.
Funding for this study was provided by the National Human Genome Research Institute and the American Lung Association.
Gina DiGravio | EurekAlert!
Satellites, airport visibility readings shed light on troops' exposure to air pollution
09.12.2016 | Veterans Affairs Research Communications
Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State
Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.
Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
09.12.2016 | Life Sciences
09.12.2016 | Ecology, The Environment and Conservation
09.12.2016 | Health and Medicine